KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $157.6 million.

  • Vertex Pharmaceuticals' Share-based Compensation fell 607.87% to $157.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $685.9 million, marking a year-over-year decrease of 180.39%. This contributed to the annual value of $685.9 million for FY2025, which is 180.39% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Share-based Compensation of $157.6 million as of Q4 2025, which was down 607.87% from $194.9 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' Share-based Compensation's 5-year high stood at $208.6 million during Q4 2023, with a 5-year trough of $103.0 million in Q3 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Share-based Compensation had a median value of $133.2 million in 2022 and averaged $144.9 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Share-based Compensation soared by 8708.52% in 2023 and then plummeted by 1955.9% in 2024.
  • Vertex Pharmaceuticals' Share-based Compensation (Quarter) stood at $118.6 million in 2021, then decreased by 5.99% to $111.5 million in 2022, then soared by 87.09% to $208.6 million in 2023, then dropped by 19.56% to $167.8 million in 2024, then dropped by 6.08% to $157.6 million in 2025.
  • Its Share-based Compensation was $157.6 million in Q4 2025, compared to $194.9 million in Q3 2025 and $167.3 million in Q2 2025.